Risk Factors for Poor Outcomes Among Patients with Extensively Drug-Resistant Tuberculosis (XDR-TB): A Scoping Review

References

• World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization; 2019. Available from: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1. Accessed September 8, 2021.
   Google Scholar
• World Health Organization. Tuberculosis. Newsroom. World Health Organization; 2021a. Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis. Accessed October 13, 2021.
   Google Scholar
• Centers for Disease Control. Highlights from the 2016 treatment of drug-susceptible tuberculosis guidelines; 2016. Available from: https://www.cdc.gov/tb/topic/treatment/guidelinehighlights.htm#:~:text=The%20preferred%20regimen%20for%20treating,months%20of%20INH%20and%20RIF. Accessed April 18, 2021.
   Google Scholar
• MacNeil A, Glaziou P, Sismanidis C, Maloney S, Floyd K. Global epidemiology of tuberculosis and progress toward achieving global targets—2017. MMWR Morb Mortal Wkly Rep. 2019;68(11):263. doi:10.15585/mmwr.mm6811a330897077
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO announces updated definitions of extensively drug-resistant tuberculosis; 2021b. Available from: https://www.who.int/news/item/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis. Accessed September 8, 2021.
   Google Scholar
• World Health Organization. Update of the WHO guidance on the treatment of drug susceptible tuberculosis; 2021c. Available from: https://www.who.int/news/item/16-04-2021-update-of-the-who-guidance-on-the-treatment-of-drug-susceptible-tuberculosis. Accessed November 1, 2021.
   Google Scholar
• Centers for Disease Control and Prevention. Highlights from the 2016 treatment of drug-susceptible tuberculosis guidelines. Available from: https://www.cdc.gov/tb/topic/treatment/guidelinehighlights.htm. Accessed November 1, 2021.
   Google Scholar
• Manjelievskaia J, Erck D, Piracha S, Schrager L. Drug-resistant TB: deadly, costly and in need of a vaccine. Trans R Soc Trop Med Hyg. 2016;110(3):186–191. doi:10.1093/trstmh/trw00626884499
   PubMed Web of Science ®Google Scholar
• Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009;4(9):e6914. doi:10.1371/journal.pone.000691419742330
   PubMed Web of Science ®Google Scholar
• Yang TW, Park HO, Jang HN, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: a retrospective study. Medicine. 2017;96(28). doi:10.1097/MD.0000000000007482
   Web of Science ®Google Scholar
• Migliori GB, De Iaco G, Besozzi G, Centis R, Cirillo DM. First tuberculosis cases in Italy resistant to all tested drugs. Weekly Release. 2007;12(20):3194. doi:10.2807/esw.12.20.03194-en
   Google Scholar
• Velayati AA, Masjedi MR, Farnia P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest. 2009;136(2):420–425. doi:10.1378/chest.08-242719349380
   PubMed Web of Science ®Google Scholar
• Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin Infect Dis. 2012b;54(4):579–581. doi:10.1093/cid/cir88922190562
   PubMed Web of Science ®Google Scholar
• Klopper M, Warren RM, Hayes C, et al. Emergence and spread of extensively and totally drug-resistant tuberculosis, South Africa. Emerg Infect Dis. 2013;19(3):449. doi:10.3201/eid1903.12024623622714
   PubMed Web of Science ®Google Scholar
• Flor de Lima B, Tavares M. Risk factors for extensively drug‐resistant tuberculosis: a review. Clin Respir J. 2014;8(1):11–23. doi:10.1111/crj.1204423875862
   PubMed Web of Science ®Google Scholar
• Cohen T, Colijn C, Wright A, Zignol M, Pym A, Murray M. Challenges in estimating the total burden of drug-resistant tuberculosis. Am J Respir Crit Care Med. 2008;177(12):1302–1306. doi:10.1164/rccm.200801-175PP18369201
   PubMed Web of Science ®Google Scholar
• Kompala T, Shenoi SV, Friedland G. Transmission of tuberculosis in resource-limited settings. Curr HIV/AIDS Rep. 2013;10(3):264–272. doi:10.1007/s11904-013-0164-x23824469
   PubMed Web of Science ®Google Scholar
• Luepke KH, Suda KJ, Boucher H, et al. Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implications. Pharmacotherapy. 2017;37(1):71–84. doi:10.1002/phar.186827859453
   PubMed Web of Science ®Google Scholar
• Sprigg K, Pietrangeli CE. Bacterial antibiotic resistance: on the Cusp of a post-antibiotic world. Curr Treat Options Infect Dis. 2019;11:42–57. doi:10.1007/s40506-019-0181-4
   Google Scholar
• Dheda K, Gumbo T, Gandhi NR, et al. Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis. Lancet Respir Med. 2014;2(4):321–338. doi:10.1016/S2213-2600(14)70031-124717628
   PubMed Web of Science ®Google Scholar
• Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet. 2010a;375(9728):1830–1843. doi:10.1016/S0140-6736(10)60410-220488523
   PubMed Web of Science ®Google Scholar
• World Health Organization. Multidrug- and extensively drug-resistant TB (M/XDR-TB); 2021d. Available from: https://www.euro.who.int/en/health-topics/communicable-diseases/tuberculosis/data-and-statistics/multidrug-and-extensively-drug-resistant-tb-mxdr-tb. Accessed November 2, 2021.
   Google Scholar
• Sotgiu G, Ferrara G, Matteelli A, et al. Epidemiology and clinical management of XDR-TB: a systematic review by TBNET. Eur Respir J. 2009;33(4):871–881. doi:10.1183/09031936.0016800819251779
   PubMed Web of Science ®Google Scholar
• Alemu A, Bitew ZW, Worku T, Gamtesa DF, Alebel A, Sabol I. Predictors of mortality in patients with drug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2021;16(6):e0253848. doi:10.1371/journal.pone.025384834181701
   PubMed Web of Science ®Google Scholar
• Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467–473. doi:10.7326/M18-085030178033
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews BMJ. 2021;372:n71. doi:10.1136/bmj.n7133782057
   PubMed Web of Science ®Google Scholar
• Cox H, Hughes J, Black J, Nicol MP. Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible? Lancet Infect Dis. 2018;18(9):e282–e287. doi:10.1016/S1473-3099(18)30104-X29548923
   PubMed Web of Science ®Google Scholar
• Jibrin YB, Ali AB, Saad ST, Kolo PM. Prevalence of treatment failure among pulmonary tuberculosis patients in federal medical centre, Gombe, Northeastern Nigeria. ISRN Infect Dis. 2013;2013:1–4. doi:10.5402/2013/461704
   Google Scholar
• Ankrah AO, van der Werf TS, de Vries EF, Dierckx RA, Sathekge MM, Glaudemans AW. PET/CT imaging of Mycobacterium tuberculosis infection. Clin Transl Imaging. 2016;4(2):131–144. doi:10.1007/s40336-016-0164-027077068
   PubMedGoogle Scholar
• Koul AN. MDRTB Then, XMDRTB Now and Then……… Totally. JMS. 2016;19(1):12–17. doi:10.33883/jms.v19i1.275
   Google Scholar
• Tabarsi P, Mardani M. Extensively drug-resistant tuberculosis: a review article. Arch Clin Infect Dis. 2012;7(3):81–84. doi:10.5812/archcid.14773
   Google Scholar
• Keshavjee S, Farmer PE. Tuberculosis, drug resistance, and the history of modern medicine. N Engl J Med. 2012;367(10):931–936. doi:10.1056/NEJMra120542922931261
   PubMed Web of Science ®Google Scholar
• Abilleira F, Brum C, von Groll A, da Silva PE. Evaluation of direct microplate nitrate reductase assay as a rapid method for the detection of multiple and extensively tuberculosis drug resistance. Biomédica. 2015;35(2):285–291. doi:10.1590/S0120-4157201500020001726535551
   PubMed Web of Science ®Google Scholar
• Kumwenda G, Chipungu G, Sloan D, Kaimila Y, Chiumya K, Pangani H. The occurrence and frequency of genomic mutations that mediate Isoniazid and Rifampicin resistance in Mycobacterium tuberculosis isolates from untreated pulmonary Tuberculosis cases in urban Blantyre, Malawi. Malawi Med J. 2018;30(1):1–5. doi:10.4314/mmj.v30i1.129868151
   PubMed Web of Science ®Google Scholar
• Dara M, Sotgiu G, Zaleskis R, Migliori GB. Untreatable tuberculosis: is surgery the answer? Eur Respir J. 2015;45(3):577–582. doi:10.1183/09031936.0022951425726530
   PubMed Web of Science ®Google Scholar
• Banin E, Hughes D, Kuipers OP. Bacterial pathogens, antibiotics and antibiotic resistance. FEMS Microbiol Rev. 2017;41(3):450–452. doi:10.1093/femsre/fux01628486583
   PubMed Web of Science ®Google Scholar
• Duffy ST. The power of detention in the management of non-compliance with tuberculosis treatment: a survey of Irish practitioners and analysis of potential legal liability. Public Health. 2009;123(1):81–85. doi:10.1016/j.puhe.2008.09.00119091360
   PubMed Web of Science ®Google Scholar
• Migliori GB, Centis R, D’Ambrosio L, et al. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? Clin Infect Dis. 2012;54(9):1379–1380. doi:10.1093/cid/cis12822492321
   PubMed Web of Science ®Google Scholar
• Amaral L, Molnar J. Potential therapy of multidrug-resistant and extremely drug-resistant tuberculosis with thioridazine. In Vivo. 2012;26(2):231–236.22351663
   PubMed Web of Science ®Google Scholar
• Therese KL, Gayathri R, Madhavan HN. Molecular biological techniques for detection of multidrug resistant tuberculosis (MDR) and extremely drug resistant tuberculosis (XDR) in clinical isolates of Mycobacterium tuberculosis. In: Understanding Tuberculosis—global Experiences and Innovative Approaches to the Diagnosis. Rijeka, Croatia: InTech; 2012:455–470.
   Google Scholar
• Dheda K, Limberis JD, Pietersen E, et al. Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. Lancet Respir Med. 2017b;5(4):269–281. doi:10.1016/S2213-2600(16)30433-728109869
   PubMed Web of Science ®Google Scholar
• Nathavitharana RR, Lederer P, Tierney DB, Nardell E. Treatment as prevention and other interventions to reduce transmission of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2019;23(4):396–404. doi:10.5588/ijtld.18.027631064617
   PubMed Web of Science ®Google Scholar
• Farnia P, Mohammad RM, Merza MA, et al. Growth and cell-division in extensive (XDR) and extremely drug resistant (XXDR) tuberculosis strains: transmission and atomic force observation. Int J Clin Exp Med. 2010;3(4):308.21072265
   PubMed Web of Science ®Google Scholar
• Joanna Briggs Institute. Critical appraisal tools; n.d. Available from: https://jbi.global/critical-appraisal-tools. Accessed November 2, 2021.
   Google Scholar
• Bowring AL, Veronese V, Doyle JS, Stoove M, Hellard M. HIV and sexual risk among men who have sex with men and women in Asia: a systematic review and meta-analysis. AIDS Behav. 2016;20(10):2243–2265. doi:10.1007/s10461-015-1281-x26781871
   PubMed Web of Science ®Google Scholar
• Xu Y, Chen X, Wang K. Global prevalence of hypertension among people living with HIV: a systematic review and meta-analysis. J Am Soc Hypertens. 2017;11(8):530–540. doi:10.1016/j.jash.2017.06.00428689734
   PubMed Web of Science ®Google Scholar
• Adalbert JR, Varshney K, Tobin R, Pajaro R. Clinical outcomes in patients co-infected with COVID-19 and Staphylococcus aureus: a scoping review. BMC Infect Dis. 2021;21(1):1–17. doi:10.1186/s12879-021-06616-433390160
   PubMed Web of Science ®Google Scholar
• Balabanova Y, Ignatyeva O, Fiebig L, et al. Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference? Thorax. 2016;71(9):854–861. doi:10.1136/thoraxjnl-2015-20763827012887
   PubMed Web of Science ®Google Scholar
• Balabanova Y, Nikolayevskyy V, Ignatyeva O, et al. Survival of civilian and prisoner drug-sensitive, multi- and extensive drug- resistant tuberculosis cohorts prospectively followed in Russia. PLoS One. 2011;6(6):e20531. doi:10.1371/journal.pone.002053121695213
   PubMed Web of Science ®Google Scholar
• Bei C, Fu M, Zhang Y, et al. Mortality and associated factors of patients with extensive drug-resistant tuberculosis: an emerging public health crisis in China. BMC Infect Dis. 2018;18(1):261. doi:10.1186/s12879-018-3169-729879908
   PubMed Web of Science ®Google Scholar
• Bhering M, Duarte R, Kritski A. Predictive factors for unfavourable treatment in MDR-TB and XDR-TB patients in Rio de Janeiro State, Brazil, 2000–2016. PLoS One. 2019;14(11):e0218299. doi:10.1371/journal.pone.021829931747405
   PubMed Web of Science ®Google Scholar
• Blöndal K, Viiklepp P, Guomundsson LJ, Altraj A. Predictors of recurrence of multidrug-resistant and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012;16(9):1228–1233. doi:10.5588/ijtld.12.003722748131
   PubMed Web of Science ®Google Scholar
• Chingonzoh R, Manesen MR, Madlavu MJ, et al. Risk factors for mortality among adults registered on the routine drug resistant tuberculosis reporting database in the Eastern Cape Province, South Africa, 2011 to 2013. PLoS One. 2018;13(8):e0202469. doi:10.1371/journal.pone.020246930133504
   PubMed Web of Science ®Google Scholar
• Frank M, Adamashvili N, Lomtadze N, et al. Long-term follow-up reveals high post-treatment mortality among patients with extensively drug-resistant (XDR) tuberculosis in the country of Georgia. Open Forum Infect Dis. 2019;6. doi:10.1093/ofid/ofz152
   Web of Science ®Google Scholar
• Gandhi NR, Andrews JR, Brust JC, et al. Risk factors for mortality among MDR-and XDR-TB patients in a high HIV prevalence setting. Int J Tuberc Lung Dis. 2012;16(1):90–97. doi:10.5588/ijtld.11.015322236852
   PubMed Web of Science ®Google Scholar
• Gandhi NR, Shah NS, Andrews JR, et al. HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med. 2010b;181(1):80–86. doi:10.1164/rccm.200907-0989OC19833824
   PubMed Web of Science ®Google Scholar
• James P, Gupta R, Christopher DJ, Thankagunam B, Veeraraghavan B. MDR-and XDR-TB among suspected drug‐resistant TB patients in a tertiary care hospital in India. Clin Respir J. 2011;5(1):19–25. doi:10.1111/j.1752-699X.2009.00184.x21159137
   PubMed Web of Science ®Google Scholar
• Javaid A, Ullah I, Masud H, et al. Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study. Clin Microbiol Infect. 2018;24(6):612–617. doi:10.1016/j.cmi.2017.09.01228970158
   PubMed Web of Science ®Google Scholar
• Kuksa L, Riekstina V, Leimane V, et al. Multi-and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes. Public Health Action. 2014;4(2):S47–S53. doi:10.5588/pha.14.004126393098
   PubMedGoogle Scholar
• Kvasnovsky CL, Cegielski JP, Erasmus R, Siwisa NO, Thomas K, der Walt ML. Extensively drug-resistant TB in Eastern Cape, South Africa: high mortality in HIV-negative and HIV-positive patients. J Acquir Immune Defic Syndr. 2011;57(2):146–152. doi:10.1097/QAI.0b013e31821190a321297482
   PubMed Web of Science ®Google Scholar
• Liu CH, Li L, Chen Z, et al. Characteristics and treatment outcomes of patients with MDR and XDR tuberculosis in a TB referral hospital in Beijing: a 13-year experience. PLoS One. 2011;6(4):e19399. doi:10.1371/journal.pone.001939921559362
   PubMed Web of Science ®Google Scholar
• O’Donnell MR, Padayatchi N, Kvasnovsky C, Werner L, Master I, Horsburgh CR Jr. Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection. Emerg Infect Dis. 2013;19(3):416–424. doi:10.3201/eid1903.12099823622055
   PubMed Web of Science ®Google Scholar
• O’Donnell MR, Pillay M, Pillay M, et al. Primary capreomycin resistance is common and associated with early mortality in patients with extensively drug-resistant tuberculosis in KwaZulu-natal, South Africa. J Acquir Immune Defic Syndr. 2015;69(5):536–543. doi:10.1097/QAI.000000000000065025886924
   PubMed Web of Science ®Google Scholar
• Olayanju O, Limberis J, Esmail A, et al. Long-term bedaquiline-related treatment outcomes in patients with extensively drug-resistant tuberculosis from South Africa. Eur Respir J. 2018;51(5):1800544. doi:10.1183/13993003.00544-201829700106
   PubMed Web of Science ®Google Scholar
• Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study. Lancet. 2014;383(9924):1230–1239. doi:10.1016/S0140-6736(13)62675-624439237
   PubMed Web of Science ®Google Scholar
• Pietersen E, Peter J, Streicher E, et al. High frequency of resistance, lack of clinical benefit, and poor outcomes in capreomycin treated South African patients with extensively drug-resistant tuberculosis. PLoS One. 2015;10(4):e0123655. doi:10.1371/journal.pone.012365525909847
   PubMed Web of Science ®Google Scholar
• Shean K, Streicher E, Pieterson E, et al. Drug-associated adverse events and their relationship with outcomes in patients receiving treatment for extensively drug-resistant tuberculosis in South Africa. PLoS One. 2013;8(5):e63057. doi:10.1371/journal.pone.006305723667572
   PubMed Web of Science ®Google Scholar
• Shin SS, Keshavjee S, Gelmanova IY, et al. Development of extensively drug-resistant tuberculosis during multidrug-resistant tuberculosis treatment. Am J Respir Crit Care Med. 2010;182(3):426–432. doi:10.1164/rccm.200911-1768OC20413630
   PubMed Web of Science ®Google Scholar
• Tang S, Tan S, Yao L, et al. Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation. PLoS One. 2013;8(12):e82943. doi:10.1371/journal.pone.008294324349402
   PubMed Web of Science ®Google Scholar
• Te Riele JB, Buser V, Calligaro G, et al. Relationship between chest radiographic characteristics, sputum bacterial load, and treatment outcomes in patients with extensively drug-resistant tuberculosis. Int J Infect Dis. 2019;79:65–71. doi:10.1016/j.ijid.2018.10.02630395979
   PubMed Web of Science ®Google Scholar
• Yuengling KA, Padayatchi N, Wolf A, et al. Effect of antiretroviral therapy on treatment outcomes in a prospective study of extensively drug-resistant tuberculosis (XDR-TB) HIV coinfection treatment in KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr. 2018;79(4):474–480. doi:10.1097/QAI.000000000000183330212394
   PubMed Web of Science ®Google Scholar
• Zhang L, Meng Q, Chen S, et al. Treatment outcomes of multidrug-resistant tuberculosis patients in Zhejiang, China, 2009–2013. Clin Microbiol Infect. 2018;24(4):381–388. doi:10.1016/j.cmi.2017.07.00828712668
   PubMed Web of Science ®Google Scholar
• Syakiratin Q, Wibowo A, Febriani E. Psychological challenges faced by multidrug-resistant tuberculosis patients: a systematic review. Berita Kedokteran Masyarakat. 2019;35(5):155–161.
   Google Scholar
• Madhav B, Iyer A, Jayalakshmi TK. Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis. Eur Respir J. 2015;46:PA2708. doi:10.1183/13993003.congress-2015.PA2708
   Web of Science ®Google Scholar
• Tola HH, Tol A, Shojaeizadeh D, Garmaroudi G. Tuberculosis treatment non-adherence and lost to follow up among TB patients with or without HIV in developing countries: a systematic review. Iran J Public Health. 2015;44(1):1–11.26060770
   PubMed Web of Science ®Google Scholar
• Widjanarko B, Gompelman M, Dijkers M, van der Werf MJ. Factors that influence treatment adherence of tuberculosis patients living in Java, Indonesia. Patient Prefer Adherence. 2009;3:231–238. doi:10.2147/ppa.s602019936166
   PubMed Web of Science ®Google Scholar
• Gebremariam MK, Bjune GA, Frich JC. Barriers and facilitators of adherence to TB treatment in patients on concomitant TB and HIV treatment: a qualitative study. BMC Public Health. 2010;10(1):651. doi:10.1186/1471-2458-10-65121029405
   PubMed Web of Science ®Google Scholar
• Chimbindi N, Bor J, Newell ML, et al. Time and money: the true costs of health care utilization for patients receiving ”Free” HIV/tuberculosis care and treatment in rural KwaZulu-Natal. J Acquir Immune Defic Syndr. 2015;70(2):e52–e60. doi:10.1097/QAI.000000000000072826371611
   PubMed Web of Science ®Google Scholar
• Central Intelligence Agency (CIA). HIV/AIDS – people living with HIV/AIDS. CIAWorld Factbook; 2020. Available from: https://www.cia.gov/the-world-factbook/field/hiv-aids-people-living-with-hiv-aids/country-comparison. Accessed December 7, 2021.
   Google Scholar
• World Health Organization. Drug-resistant TB: totally drug-resistant TB FAQ. Areas of work: World Health Organization; 2020. Available from: https://www.who.int/tb/areas-of-work/drug-resistant-tb/totally-drug-resistant-tb-faq/en/. Accessed April 22, 2020.
   Google Scholar
• World Health Organization. Drug-resistant TB: XDR-TB FAQ. World Health Organization; 2020. Available from: https://www.who.int/tb/areas-of-work/drug-resistant-tb/xdr-tb-faq/en/. Accessed June 3, 2020.
   Google Scholar
• de Almeida CPB, Ziegelmann PK, Couban R, Wang L, Busse JW, Silva DR. Predictors of in-hospital mortality among patients with pulmonary tuberculosis: a systematic review and meta-analysis. Sci Rep. 2018;8(1):1–8. doi:10.1038/s41598-018-25409-529311619
   PubMed Web of Science ®Google Scholar
• Waitt CJ, Squire SB. A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int J Tuberc Lung Dis. 2010;15:871–885. doi:10.5588/ijtld.10.0352
   Web of Science ®Google Scholar
• World Health Organization. Addressing TB comorbidities and health-related risk factors; 2021e. Available from: https://www.who.int/activities/addressing-tb-comorbidities-and-health-related-risk-factors. Accessed November 2, 2021.
   Google Scholar
• Stockbridge EL, Kabani FA, Gallups JS, Miller TL. Ramadan and culturally competent care: strengthening tuberculosis protections for recently resettled Muslim refugees. J Public Health Manag Pract. 2020;26(5):E13–E16. doi:10.1097/PHH.000000000000089332732732
   PubMed Web of Science ®Google Scholar
• Hoke T, Bateganya M, Toyo O, et al. How home delivery of antiretroviral drugs ensured uninterrupted HIV treatment during COVID-19: experiences from Indonesia, Laos, Nepal, and Nigeria. Global Health: Science and Practice; 2021.
   Google Scholar
• Mash R, Christian C, Chigwanda RV. Alternative mechanisms for delivery of medication in South Africa: a scoping review. S Afr Fam Pract. 2021;63(1). doi:10.4102/safp.v63i1.5274
   Google Scholar
• Pasha A, Siddiqui H, Ali S, Brooks MB, Maqbool NR, Khan AJ. Impact of integrating mental health services within existing tuberculosis treatment facilities. Med Access Point Care. 2021;5:23992026211011314. doi:10.1177/23992026211011314
   Google Scholar
• World Health Organization. Tuberculosis patient cost surveys: a handbook. Geneva: World Health Organization; 2017. Available from: https://apps.who.int/iris/handle/10665/259701. Accessed November 2, 2021.
   Google Scholar
• Gurung SC, Dixit K, Rai B, et al. The role of active case finding in reducing patient incurred catastrophic costs for tuberculosis in Nepal. Infect Dis Poverty. 2019;8:99. doi:10.1186/s40249-019-0603-z31791412
   PubMed Web of Science ®Google Scholar
• World Health Organization. Mozambique – a comprehensive community-based delivery intervention for TB. Available from: https://apps.who.int/iris/bitstream/handle/10665/337105/9789240013575-eng.pdf. Accessed November 2, 2021.
   Google Scholar
• Vo LNQ, Forse RJ, Codlin AJ, et al. Socio-protective effects of active case finding on catastrophic costs from tuberculosis in Ho Chi Minh City, Viet Nam: a longitudinal patient cost survey. BMC Health Serv Res. 2021;21(1):1–11. doi:10.1186/s12913-021-06984-233388053
   PubMed Web of Science ®Google Scholar
• Boccia D, Hargreaves J, Lönnroth K, et al. Cash transfer and microfinance interventions for tuberculosis control: review of the impact evidence and policy implications. Int J Tuberc Lung Dis. 2011;15(Suppl2):37–49. doi:10.5588/ijtld.10.043821740658
   PubMedGoogle Scholar